$5.72
-0.56(-8.93%)
Mkt Cap $4M
$5.66
$10.95
52-Week Range
At A Glance
1
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in S...
2
Most recently: Current Report on Form 6-K (2026-02-03).
$4M
Market Cap
$1.1K
Revenue
-$49.9K
Net Income
Employees2
Fundamentals
How The Business Makes Money
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
Industry Biotechnology
Activity
Company Profile
CIK0001574232
ISINUS00654J2069
CUSIP00654J107
Phone41 22 884 1555
AddressChemin des Mines, 9, Geneva, 1202, CH
SEC EDGAR